X

Trial Profile

Double-blind Comparative Study of SYR-472

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trelagliptin (Primary) ; Alogliptin
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use
Sponsors Takeda

Most Recent Events

26 Mar 2015 According to Takeda Pharmaceuticals media release, based on the results of this and other phase III trials ( see profile 226639 and 206116), Japanese Ministry of Health, Labour and Welfare has approved the New Drug Application of Zafatek (trelagliptin succinate).
19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
17 Sep 2014 Results published in the Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com